I'm also in it for the long haul, so I'm not worried about the...

I'm also in it for the long haul, so I'm not worried about the short term price movement. Hopefully updates on patient recruitment numbers will boost the share price.

And I know most on this thread won't agree (and I keep banging on about it), but some pre-clinical studies demonstrating efficacy in another disease group with a larger TAM will definitely push the SP in the right direction. I think it'll generate some wider interest in the market (and with instos) and de-risk the proposition. They did say that, when this trial is set up, they will focus some energy on another indication, so hopefully we're not too far way from that.